Rajni Kumari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rajni Kumari has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Ulrich Steidl
Albert Einstein College of Medicine
22 shared publications - Amit Verma
Albert Einstein College of Medicine
20 shared publications - Aditi Shastri
Albert Einstein College of Medicine
15 shared publications - Advaitha Madireddy
Rutgers Cancer Institute of New Jersey, New Brunswick, USA
15 shared publications - Alexander James Silver
Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
15 shared publications - Amittha Wickrema
Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois
15 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Chemotherapy resistance remains a critical challenge in the treatment of patients with cancer, including acute myeloid leukemia (AML). Although genetic alterations can contribute to resistance, the role of rapid-adaptive nongenetic mechanisms, particularly transcription dynamics, remains poorly understood. In this article, we demonstrate that short-term treatment of AML cells with the widely used chemotherapeutic cytarabine (AraC) leads to the rapid emergence of a cell population with significant RNA induction and increased AraC resistance in cell lines and primary patient samples. Mechanistically, transcriptomic and targeted high-resolution analysis of transcription dynamics using single-molecule RNA FISH revealed rapid induction of transcriptional dynamics and upregulation of key transcription factors (TF)—which we term “AraC rapid response TFs.” Functionally, short-term pre- and cotreatment with RNA transcription inhibitors suppressed chemotherapy-induced RNA induction and prevented resistance acquisition in vitro and in vivo. Furthermore, CRISPR-mediated suppression of TFs PU.1 and GATA1 significantly attenuated AraC resistance. Our findings reveal a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance.Significance:This study reveals a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance, highlighting master TFs as key regulators. These insights offer a pharmacologically accessible approach to potentially alleviate the major clinical problem of chemotherapy resistance.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Chemotherapy resistance remains a critical challenge in the treatment of patients with cancer, including acute myeloid leukemia (AML). Although genetic alterations can contribute to resistance, the role of rapid-adaptive nongenetic mechanisms, particularly transcription dynamics, remains poorly understood. In this article, we demonstrate that short-term treatment of AML cells with the widely used chemotherapeutic cytarabine (AraC) leads to the rapid emergence of a cell population with significant RNA induction and increased AraC resistance in cell lines and primary patient samples. Mechanistically, transcriptomic and targeted high-resolution analysis of transcription dynamics using single-molecule RNA FISH revealed rapid induction of transcriptional dynamics and upregulation of key transcription factors (TF)—which we term “AraC rapid response TFs.” Functionally, short-term pre- and cotreatment with RNA transcription inhibitors suppressed chemotherapy-induced RNA induction and prevented resistance acquisition in vitro and in vivo. Furthermore, CRISPR-mediated suppression of TFs PU.1 and GATA1 significantly attenuated AraC resistance. Our findings reveal a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance.Significance:This study reveals a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance, highlighting master TFs as key regulators. These insights offer a pharmacologically accessible approach to potentially alleviate the major clinical problem of chemotherapy resistance.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S6 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Table 1: Key Reagents & Resources. Table 2: WES. Table 3: Primers and sgRNAs. Table 4: GSEA. Table 5: SmFISH probes. Table 6: Patient samples.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S6 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Table 1: Key Reagents & Resources. Table 2: WES. Table 3: Primers and sgRNAs. Table 4: GSEA. Table 5: SmFISH probes. Table 6: Patient samples.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Key Resources Table S1 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Key Resources Table S1 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessKey Resources Table S1 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Key Resources Table S1 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S9 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Figure S1. The effects of short-term AraC treatment on RNA transcription dynamics and AraC resistance acquisition. Figure S2.Absence of genetic clonal selection in rapid AraC resistance development. Figure S3. Suppression of RNA induction interferes with the acquisition of AraC resistance in NB4 and MOLM14. Figure S4. Transcriptomic profiling identifies key role of AraC-rapid response TFs (ARRTFs) in acquisition of drug resistance. Figure S5. Not all hematopoiesis-related TFs are transcriptionally activated following AraC treatment. Figure S6. Transcription dynamics after AraC treatment inNB4. Figure S7. Modest changes in chromatin accessibility (detected by ATACseq) during the development of rapidAraC drug resistance. Figure S8. Flow cytometry gating strategy for analyzing RNA dynamics in hematopoietic stem and progenitor cells (HSPCs) of AMLpatient samples. Figure S9. Evaluation of cell proliferation of control and TF-KO subclones in steady state.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S9 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Figure S1. The effects of short-term AraC treatment on RNA transcription dynamics and AraC resistance acquisition. Figure S2.Absence of genetic clonal selection in rapid AraC resistance development. Figure S3. Suppression of RNA induction interferes with the acquisition of AraC resistance in NB4 and MOLM14. Figure S4. Transcriptomic profiling identifies key role of AraC-rapid response TFs (ARRTFs) in acquisition of drug resistance. Figure S5. Not all hematopoiesis-related TFs are transcriptionally activated following AraC treatment. Figure S6. Transcription dynamics after AraC treatment inNB4. Figure S7. Modest changes in chromatin accessibility (detected by ATACseq) during the development of rapidAraC drug resistance. Figure S8. Flow cytometry gating strategy for analyzing RNA dynamics in hematopoietic stem and progenitor cells (HSPCs) of AMLpatient samples. Figure S9. Evaluation of cell proliferation of control and TF-KO subclones in steady state.
- Open Access
- 18 May 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (4) , 624-641
Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Chemotherapy resistance remains a critical challenge in the treatment of patients with cancer, including acute myeloid leukemia (AML). Although genetic alterations can contribute to resistance, the role of rapid-adaptive nongenetic mechanisms, particularly transcription dynamics, remains poorly understood. In this article, we demonstrate that short-term treatment of AML cells with the widely used chemotherapeutic cytarabine (AraC) leads to the rapid emergence of a cell population with significant RNA induction and increased AraC resistance in cell lines and primary patient samples. Mechanistically, transcriptomic and targeted high-resolution analysis of transcription dynamics using single-molecule RNA FISH revealed rapid induction of transcriptional dynamics and upregulation of key transcription factors (TF)—which we term “AraC rapid response TFs.” Functionally, short-term pre- and cotreatment with RNA transcription inhibitors suppressed chemotherapy-induced RNA induction and prevented resistance acquisition in vitro and in vivo. Furthermore, CRISPR-mediated suppression of TFs PU.1 and GATA1 significantly attenuated AraC resistance. Our findings reveal a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance. Significance: This study reveals a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance, highlighting master TFs as key regulators. These insights offer a pharmacologically accessible approach to potentially alleviate the major clinical problem of chemotherapy resistance.
- 18 May 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (4) , 624-641
Open AccessRapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Chemotherapy resistance remains a critical challenge in the treatment of patients with cancer, including acute myeloid leukemia (AML). Although genetic alterations can contribute to resistance, the role of rapid-adaptive nongenetic mechanisms, particularly transcription dynamics, remains poorly understood. In this article, we demonstrate that short-term treatment of AML cells with the widely used chemotherapeutic cytarabine (AraC) leads to the rapid emergence of a cell population with significant RNA induction and increased AraC resistance in cell lines and primary patient samples. Mechanistically, transcriptomic and targeted high-resolution analysis of transcription dynamics using single-molecule RNA FISH revealed rapid induction of transcriptional dynamics and upregulation of key transcription factors (TF)—which we term “AraC rapid response TFs.” Functionally, short-term pre- and cotreatment with RNA transcription inhibitors suppressed chemotherapy-induced RNA induction and prevented resistance acquisition in vitro and in vivo. Furthermore, CRISPR-mediated suppression of TFs PU.1 and GATA1 significantly attenuated AraC resistance. Our findings reveal a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance. Significance: This study reveals a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance, highlighting master TFs as key regulators. These insights offer a pharmacologically accessible approach to potentially alleviate the major clinical problem of chemotherapy resistance.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Elevated Clonal Hematopoiesis in 9/11 First Responders Has Distinct Age-related Patterns and Relies on IL1RAP for Clonal Expansion
Prevalence of somatic mutation (VAF ≤ 25%) in WTC-exposed responders
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Elevated Clonal Hematopoiesis in 9/11 First Responders Has Distinct Age-related Patterns and Relies on IL1RAP for Clonal Expansion
Prevalence of somatic mutation (VAF ≤ 25%) in WTC-exposed responders
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Elevated Clonal Hematopoiesis in 9/11 First Responders Has Distinct Age-related Patterns and Relies on IL1RAP for Clonal Expansion
Mutational signatures for changes seen in WTC-exposed responders below the age of 60
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Elevated Clonal Hematopoiesis in 9/11 First Responders Has Distinct Age-related Patterns and Relies on IL1RAP for Clonal Expansion
Mutational signatures for changes seen in WTC-exposed responders below the age of 60
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Elevated Clonal Hematopoiesis in 9/11 First Responders Has Distinct Age-related Patterns and Relies on IL1RAP for Clonal Expansion
Environmental exposures are linked to precancerous hematologic conditions, but studies in cohorts with well-defined exposures are limited. We sequenced blood samples from a large cohort of first responders exposed to the aerosolized dust and carcinogens from the 9/11 World Trade Center (WTC) disaster and observed a significantly higher prevalence of clonal hematopoiesis (CH) mutations when compared with two sets of control cohorts after controlling for age, race, and sex. Younger exposed first responders exhibited unconventional CH mutations, with defective DNA repair signatures. Leukemia risk was elevated (3.7% vs. 0.6%; OR = 5.73) in WTC-exposed responders with CH versus without CH. Exposure to particulate matter collected from WTC site impaired healthy stem cells while expanding Tet2-mutant CH clones in mice. The inflammation sensor IL1RAP was overexpressed in murine CH, and genetic knockdown inhibited mutant clone growth in vivo. This study links discrete environmental exposure to hematopoietic mutations and leukemia, identifying IL1RAP as a novel therapeutic target in CH.Significance:This study identifies elevated CH with distinct, nonclassical mutations in 9/11 first responders, particularly younger individuals, and links CH to increased leukemia risk. Findings suggest broader relevance to other genotoxic environmental exposures and highlight IL1RAP as a critical driver of CH expansion and a promising therapeutic target for inflammation-driven malignancies.See related commentary by Safina and van Galen, p. 2406
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Elevated Clonal Hematopoiesis in 9/11 First Responders Has Distinct Age-related Patterns and Relies on IL1RAP for Clonal Expansion
Environmental exposures are linked to precancerous hematologic conditions, but studies in cohorts with well-defined exposures are limited. We sequenced blood samples from a large cohort of first responders exposed to the aerosolized dust and carcinogens from the 9/11 World Trade Center (WTC) disaster and observed a significantly higher prevalence of clonal hematopoiesis (CH) mutations when compared with two sets of control cohorts after controlling for age, race, and sex. Younger exposed first responders exhibited unconventional CH mutations, with defective DNA repair signatures. Leukemia risk was elevated (3.7% vs. 0.6%; OR = 5.73) in WTC-exposed responders with CH versus without CH. Exposure to particulate matter collected from WTC site impaired healthy stem cells while expanding Tet2-mutant CH clones in mice. The inflammation sensor IL1RAP was overexpressed in murine CH, and genetic knockdown inhibited mutant clone growth in vivo. This study links discrete environmental exposure to hematopoietic mutations and leukemia, identifying IL1RAP as a novel therapeutic target in CH.Significance:This study identifies elevated CH with distinct, nonclassical mutations in 9/11 first responders, particularly younger individuals, and links CH to increased leukemia risk. Findings suggest broader relevance to other genotoxic environmental exposures and highlight IL1RAP as a critical driver of CH expansion and a promising therapeutic target for inflammation-driven malignancies.See related commentary by Safina and van Galen, p. 2406
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Elevated Clonal Hematopoiesis in 9/11 First Responders Has Distinct Age-related Patterns and Relies on IL1RAP for Clonal Expansion
Mutational signatures for changes seen in WTC-exposed responders above the age of 60
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Elevated Clonal Hematopoiesis in 9/11 First Responders Has Distinct Age-related Patterns and Relies on IL1RAP for Clonal Expansion
Mutational signatures for changes seen in WTC-exposed responders above the age of 60